— Know what they know.
Not Investment Advice

FENC

Fennec Pharmaceuticals Inc.
1W: -17.4% 1M: -30.8% 3M: -19.8% YTD: -19.7% 1Y: -6.5% 3Y: -23.6% 5Y: -14.7%
$6.17
+0.15 (+2.49%)
After Hours: $6.57 (+0.40, +6.48%)
NASDAQ · Healthcare · Biotechnology · $176.3M · Alpha Radar Sell · Power 33
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$176.3M
52W Range4.68-9.92
Volume371,746
Avg Volume150,827
Beta1.45
Dividend
Analyst Ratings
7 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOJeffrey S. Hackman
Employees32
SectorHealthcare
IndustryBiotechnology
IPO Date2017-09-15
68 TW Alexander Drive
Research Triangle Park, NC 27709
US
919 636 4530
About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Recent Insider Trades

NameTypeSharesPriceDate
Raykov Rosty M-Exempt 15,598 $2.45 2026-03-02
Raykov Rosty S-Sale 10,079 $8.36 2026-03-02
Raykov Rosty M-Exempt 15,598 $2.45 2026-03-02
Andrade Robert A-Award 1,191 2026-02-28
Raykov Rosty A-Award 5,208 2026-02-28

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms